{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:52:55Z","timestamp":1781610775429,"version":"3.54.5"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA0919100"],"award-info":[{"award-number":["2024YFA0919100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970617"],"award-info":[{"award-number":["81970617"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571835"],"award-info":[{"award-number":["82571835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013099","name":"Scientific Research Fund of Liaoning Provincial Education Department","doi-asserted-by":"publisher","award":["JYTMS20230078"],"award-info":[{"award-number":["JYTMS20230078"]}],"id":[{"id":"10.13039\/501100013099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013099","name":"Scientific Research Fund of Liaoning Provincial Education Department","doi-asserted-by":"publisher","award":["2024JH6\/100800029"],"award-info":[{"award-number":["2024JH6\/100800029"]}],"id":[{"id":"10.13039\/501100013099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018617","name":"Liaoning Revitalization Talents Program","doi-asserted-by":"publisher","award":["XLYC2412068"],"award-info":[{"award-number":["XLYC2412068"]}],"id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>IgA nephropathy (IgAN) is characterized by the mesangial deposition of IgA. Its pathogenesis is driven by increased production of galactose-deficient IgA1 (Gd-IgA1) by activated B cells. Telitacicept offers a therapeutic approach for IgAN by inhibiting B-cell activation. This study aimed to investigate the efficacy and safety of telitacicept in patients with refractory IgAN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study involved 9 patients with refractory IgAN who had received corticosteroids or immune modulators for at least one year before telitacicept treatment was initiated. The patients received subcutaneous telitacicept for 12 months (160\u2005mg every week for the first 6 months), and the dose was then tapered to 160\u2005mg every two weeks during the following 6 months. The follow-up period included the 12 months of telitacicept therapy and 6 months after drug withdrawal. We collected the patients\u2019 laboratory data throughout the follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 12 months of telitacicept therapy, all patients achieved complete remission of proteinuria, and their estimated glomerular filtration rate (eGFR) exceeded the baseline level prior to treatment. Following a 6-month drug withdrawal, all patients remained in complete remission of proteinuria, and the eGFR levels did not significantly differ from those recorded at the end of the twelfth month of therapy. At the last follow-up, six patients successfully discontinued conventional IgAN drugs. No serious adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Telitacicept effectively reduced proteinuria and improved kidney function in patients with refractory IgAN. The therapeutic benefits were maintained after the discontinuation of telitacicept.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag012","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:33:28Z","timestamp":1768048408000},"page":"344-352","source":"Crossref","is-referenced-by-count":0,"title":["Telitacicept for refractory IgA nephropathy: a case series"],"prefix":"10.1093","volume":"39","author":[{"given":"Xun-Jie","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of China Medical University , Shenyang, Liaoning 110001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of China Medical University , Shenyang, Liaoning 110001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Guang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of China Medical University , Shenyang, Liaoning 110001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of China Medical University , Shenyang, Liaoning 110001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Xin","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of China Medical University , Shenyang, Liaoning 110001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Nan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of China Medical University , Shenyang, Liaoning 110001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5283-8636","authenticated-orcid":false,"given":"Lin-Lin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of China Medical University , Shenyang, Liaoning 110001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026061607055873800_aajag012-B1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","article-title":"Current treatment of IgA nephropathy","volume":"43","author":"Floege","year":"2021","journal-title":"Semin Immunopathol"},{"key":"2026061607055873800_aajag012-B2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis."},{"key":"2026061607055873800_aajag012-B3","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026061607055873800_aajag012-B4","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1093\/ndt\/gfad146","article-title":"Iga nephropathy in adults-treatment standard","volume":"38","author":"Gleeson","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026061607055873800_aajag012-B5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2215\/CJN.0000000000000338","article-title":"Targeting APRIL in the treatment of IgA nephropathy","volume":"19","author":"Cheung","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026061607055873800_aajag012-B6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/ki.2011.501","article-title":"An update on the pathogenesis and treatment of IgA nephropathy","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int"},{"key":"2026061607055873800_aajag012-B7","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","article-title":"The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy","volume":"16","author":"Yeo","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026061607055873800_aajag012-B8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2026061607055873800_aajag012-B9","doi-asserted-by":"publisher","first-page":"1346769","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2024","journal-title":"Front Nephrol"},{"key":"2026061607055873800_aajag012-B10","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1182\/blood-2006-08-041772","article-title":"TACI regulates IgA production by APRIL in collaboration with HSPG","volume":"109","author":"Sakurai","year":"2007","journal-title":"Blood"},{"key":"2026061607055873800_aajag012-B11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/ni.1914","article-title":"The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88","volume":"11","author":"He","year":"2010","journal-title":"Nat Immunol"},{"key":"2026061607055873800_aajag012-B12","doi-asserted-by":"publisher","first-page":"1169084","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"2026061607055873800_aajag012-B13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026061607055873800_aajag012-B14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2026061607055873800_aajag012-B15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/rheumatology\/kead674","article-title":"The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis","volume":"674","author":"Chen","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026061607055873800_aajag012-B16","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"2026061607055873800_aajag012-B17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"2026061607055873800_aajag012-B18","doi-asserted-by":"publisher","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026061607055873800_aajag012-B19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","article-title":"TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy","volume":"97","author":"Makita","year":"2020","journal-title":"Kidney Int"},{"key":"2026061607055873800_aajag012-B20","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"2026061607055873800_aajag012-B21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cellimm.2006.08.002","article-title":"BAFF induces a hyper-IgA syndrome in the intestinal lamina propria concomitant with IgA deposition in the kidney independent of LIGHT","volume":"241","author":"McCarthy","year":"2006","journal-title":"Cell Immunol"},{"key":"2026061607055873800_aajag012-B22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"2026061607055873800_aajag012-B23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.revmed.2016.02.016","article-title":"Role of B cells in the pathogenesis of systemic sclerosis","volume":"38","author":"Sanges","year":"2017","journal-title":"Rev Med Interne"},{"key":"2026061607055873800_aajag012-B24","doi-asserted-by":"publisher","first-page":"R168","DOI":"10.1186\/ar4352","article-title":"B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis","volume":"15","author":"Fran\u00e7ois","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"2026061607055873800_aajag012-B25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000446354","article-title":"A systematic review and meta-analysis of kidney and pregnancy outcomes in IgA nephropathy","volume":"44","author":"Liu","year":"2016","journal-title":"Am J Nephrol"},{"key":"2026061607055873800_aajag012-B26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12884-024-06632-7","article-title":"Successful pregnancy in a patient with IgA nephropathy treated with telitacicept: a case report","volume":"24","author":"Du","year":"2024","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/2\/344\/68345637\/aajag012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/2\/344\/68345637\/aajag012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:10:01Z","timestamp":1781608201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/2\/344\/8688151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,20]]},"published-print":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag012","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}